GNTA Genenta Science S.p.A.
USHealthcareAs of 2026-07-09 16:00
Why GNTA matters now
Genenta Science S.p.A. (GNTA) is a US stock in Healthcare. The latest InvestLog snapshot shows $1.59 with +3.92% on the session and $30.4M in market capitalization; recent performance reads 1-month +169.58% and YTD +12.75%.
The latest financial table shown here is Q4 2025, with revenue of $0.00, net income of $-2.7M, and EPS of $-0.13. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -27.6%.
The latest indexable market news headline is "Genenta signs Definitive Agreements with Sophia High Tech" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $—; recent insider activity includes Paracchi Pierluigi filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
1.42
P/S
0.00
EV/EBITDA
-5.15
DCF Value
$-0.13
FCF Yield
-27.6%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-36.8%
ROA
-19.6%
ROIC
-21.3%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $0.00 | $-2.7M | $-0.13 |
| FY 2025 | $0.00 | $-6.3M | $-0.33 |
| Q2 2025 | $0.00 | $-3.6M | $-0.20 |
| Q4 2024 | $0.00 | $-5.1M | $-0.27 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
IT
Exchange
—
Beta
0.90
Genenta Science S.p.A. is an Italian clinical-stage biotechnology firm focused on pioneering hematopoietic stem cell gene therapies to combat solid tumors. Its primary therapeutic candidate, Temferon, is currently undergoing Phase 1/2a clinical evaluation. This innovative therapy is being developed to treat glioblastoma multiforme, specifically targeting patients whose tumors exhibit an unmethylated MGMT gene promoter. Beyond this, Genenta Science is exploring Temferon's potential application in various other solid tumor types, including locally advanced hepatocellular carcinoma and intra-hepatic cholangiocarcinoma. Established in 2014, the company maintains its headquarters in Milan, Italy.